Agios Pharm (AGIO) — Cash Flow-to-Debt Ratio
Agios Pharm (AGIO) has a Cash Flow-to-Debt Ratio of -1.57x as of March 2026, meaning its operating cash flow of $-118.92 Million could theoretically repay -2% of its total liabilities ($75.88 Million) in one year. See Agios Pharm free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Agios Pharm Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Agios Pharm across 15 annual periods. Also explore net asset growth rate of Agios Pharm to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Agios Pharm (2011–2025)
Year-by-year debt coverage analysis for Agios Pharm. For market capitalisation and broader financial context, see Agios Pharm stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.58x | $-372.98 Million | $104.11 Million | ▼ -12.3% |
| 2024 | -3.19x | $-389.84 Million | $122.24 Million | ▼ -35.8% |
| 2023 | -2.35x | $-296.06 Million | $126.10 Million | ▼ -4.6% |
| 2022 | -2.24x | $-309.48 Million | $137.90 Million | ▲ +19.7% |
| 2021 | -2.79x | $-407.32 Million | $145.76 Million | ▼ -335.8% |
| 2020 | -0.64x | $-290.76 Million | $453.45 Million | ▲ +56.7% |
| 2019 | -1.48x | $-370.62 Million | $250.21 Million | ▲ +16.8% |
| 2018 | -1.78x | $-304.42 Million | $170.92 Million | ▼ -49.2% |
| 2017 | -1.19x | $-285.23 Million | $238.89 Million | ▼ -906.6% |
| 2016 | 0.15x | $38.56 Million | $260.50 Million | ▲ +114.4% |
| 2015 | -1.03x | $-76.95 Million | $74.95 Million | ▼ -16.8% |
| 2014 | -0.88x | $-59.35 Million | $67.54 Million | ▼ -8.6% |
| 2013 | -0.81x | $-56.40 Million | $69.72 Million | ▼ -52.0% |
| 2012 | -0.53x | $-49.55 Million | $93.11 Million | ▼ -359.2% |
| 2011 | -0.12x | $-15.22 Million | $131.33 Million | — |